Erratum to: Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism
Authors:
Yunliang Chen, Andrew Leask, David J Abraham, Laura Kennedy, Xu Shi-wen, Christopher P Denton, Carol M Black, Liaquat S Verjee, Mark Eastwood
After publication of this work [1], the authors became aware of some errors in the figures with respect to the loading controls for the western blots in Figure Two panel A (Figure 1 here), Figure Five panel B (Figure 2 here) and Figure Six panel A (Figure 3 here). These errors were due to genuine mistakes in generating the figures from templates and incorrect cropping of the western blot X-ray film images. These errors had no impact on the scientific conclusions of the article. The experiments reported in these figures have been repeated and new images produced.
Erratum to: Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism
Authors
Yunliang Chen Andrew Leask David J Abraham Laura Kennedy Xu Shi-wen Christopher P Denton Carol M Black Liaquat S Verjee Mark Eastwood
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.